Head to Head, GA101 Trumps Rituxan in Chronic Lymphocytic Leukemia
Genentech Inc., a unit of the Roche Group, received the confirmation on lead hematology candidate GA101 (obinutuzumab) it's been awaiting since an interim analysis at the end of January showed marked improvement in progression-free survival (PFS) in a Phase III trial in previously untreated chronic lymphocytic leukemia (CLL).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST